Atlas Energy（CANS.F）株式概要バイオテクノロジー企業であるウィロー・バイオサイエンシズ社は、米国でコンシューマーケア、食品・飲料、医薬品向けの植物由来成分を開発、生産、販売している。 詳細CANS.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( CA$0 )株式の流動性は非常に低い 意味のある時価総額がありません ( $58M )すべてのリスクチェックを見るCANS.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW483,546 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA483,546 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.087該当なし内在価値ディスカウントEst. Revenue$PastFuture-45m2m2016201920222025202620282031Revenue CA$0.6Earnings CA$0.1AdvancedSet Fair ValueView all narrativesAtlas Energy Corp. 競合他社Mereo BioPharma GroupSymbol: NasdaqCM:MREOMarket cap: US$46.4mLite StrategySymbol: NasdaqCM:LITSMarket cap: US$33.7mINmune BioSymbol: NasdaqCM:INMBMarket cap: US$45.7maTyr PharmaSymbol: NasdaqCM:ATYRMarket cap: US$48.8m価格と性能株価の高値、安値、推移の概要Atlas Energy過去の株価現在の株価CA$0.08752週高値CA$0.1552週安値CA$0.046ベータ4.741ヶ月の変化-17.07%3ヶ月変化-27.66%1年変化-40.89%3年間の変化-79.78%5年間の変化-97.57%IPOからの変化-99.13%最新ニュースお知らせ • Jul 06Atlas Energy Corp., Annual General Meeting, Aug 06, 2026Atlas Energy Corp., Annual General Meeting, Aug 06, 2026.お知らせ • Jun 22Atlas Energy Corp. Announces Appointments to Subsidiary BoardAtlas Energy Corp. announced that Patrick Drouin and Dion Degrand will be appointed to the board of directors of Atlas Energy International SEZC, the Company’s Cayman Islands subsidiary, subject to receipt of applicable Cayman Islands regulatory approvals. Patrick Drouin is the President of Wheaton Precious Metals International and Chief Sustainability Officer for the Wheaton group. Before being appointed President in October 2023, Mr. Drouin was the Senior Vice President of Sustainability & Investor Relations at Wheaton Precious Metals, an executive role primarily responsible for the company’s sustainability efforts and engaging with the investment community. Prior to Wheaton, Mr. Drouin worked for UBS Securities from 2001 to 2012 in institutional equity sales across North America and Europe, most recently in London as Head of European Sales for UBS Canada. In this role, Mr. Drouin built a sales platform responsible for advising fund managers on Canadian equities. Throughout his advisory career, he has focused on the resource sector. Prior to UBS, he served as a Project Geologist in the San Francisco Bay Area for William Lettis & Associates. Mr. Drouin has an MBA from the Rotman School of Management, University of Toronto, and a Masters in Geology from the University of Memphis. Dion Degrand is the Chief Executive Officer of the Rawlinson & Hunter group of companies in the Cayman Islands, providing a full range of professional services including fiduciary, trust and corporate, fund governance and administration, accounting, restructuring and compliance services to international clients. Mr. Degrand has over 30 years of experience across investment banking, public and private capital markets, accounting, international banking, and independent governance. Prior to relocating to the Cayman Islands, Mr. Degrand spent the majority of his career in oil and gas investment banking, holding senior positions at leading investment banks, including Head of Canadian Energy at Raymond James (Canada), Head of Energy and Head of Western Canada at Cormark Securities, Managing Director at National Bank Financial and Principal at Peters & Co. Limited. Mr. Degrand is a CA, CPA and CFA charterholder, and a CIMA-registered director under the Cayman Islands Directors Registration and Licensing Act.お知らせ • Jun 19+ 2 more updatesWillow Biosciences Inc. Announces Board and Executive AppointmentsWillow Biosciences Inc. announced the new management team and new board were appointed concurrently with the completion of the Private Placement, led by Mark Hodgson as President and Richard Naden as a Senior Executive and including Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price as directors. In addition, Sanjib (Sony) Gill, a partner in the Calgary office of the national law firm Stikeman Elliott LLP, will act as Corporate Secretary. The new management team expects to focus on investing in producing and growth-oriented oil and gas assets aligned with their prior operating expertise. With a disciplined and diversified strategy, the Company will aim to acquire economic interests in undercapitalized assets that have been overlooked amid recent shifts in capital allocation within the industry. The new management team is actively evaluating numerous opportunities.お知らせ • May 07Willow Biosciences Inc. announced that it expects to receive CAD 30 million in fundingWillow Biosciences Inc. announced a private placement of 3,000,000,000 common shares and units at a price of CAD 0.01 for the gross proceeds of CAD 30,000,000 on May 7, 2025. Each unit will consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of CAD 0.01 per share. The Company may pay fees to certain advisory firms that assist in the placement of the Private Placement. Units will be issued to subscribers that are members of the New Executive Team and the New Board, together with certain additional subscribers identified by such persons. Common Shares will be issued to all other subscribers. The New Executive Team will be led by Mark Hodgson as President and Chief Executive Officer, Travis Doupe as Chief Financial Officer, Don Kornelsen as Vice President, Commercial, Ryan Giroux as Vice President, Corporate Development and Blair Anderson as Vice President, Geoscience of the Company and Richard Naden as a Senior Executive. The New Board will be comprised of Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price.お知らせ • May 02+ 1 more updateWillow Biosciences Inc. Announces CEO ChangesWillow Biosciences Inc. announced the completion of the sale (the Transaction) of its wholly-owned operating subsidiary, Epimeron USA Inc. As a condition to the completion of the Transaction, Dr. Chris Savile, Chief Executive Officer of the Company resigned from the role with the Company to join the Purchaser. Travis Doupe, Chief Financial Officer of the Company, has been appointed to the role of Interim Chief Executive Officer effective April 30, 2025.お知らせ • May 01Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million.Mycofeast Ltd entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million on March 14, 2025. The acquisition includes the Company's biotechnology business, intellectual property and R&D team. The consideration is subject to working capital and net debt closing adjustments. Closing of the Transaction is expected to occur on or about April 30, 2025, subject to customary closing conditions. The Transaction must be approved by shareholders holding at least 66.67% of shares voted in person or by proxy at an annual general and special meeting of shareholders, which will be held April 25, 2025 (the "Meeting"). The Transaction has been approved unanimously by Willow's Board of Directors, which has determined that the Transaction is in the best interests of Willow and its shareholders and unanimously recommends that shareholders vote in favour of approving the Transaction at the Meeting. Willow's major shareholders, Directors and Officers, who collectively control approximately 22.17% of the outstanding common shares of Willow, have each entered into a voting support agreement pursuant to which they have irrevocably agreed to vote all common shares in favour of the Transaction at the Meeting. The Company intends to apply a portion of the net proceeds to debt reduction, and will retain the remainder of the proceeds pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value. Willow Biosciences Inc. must pay $0.5 million to Mycofeast Ltd if it terminates the deal. The deal is expected to be closed before April 30, 2025. Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million on April 30, 2025.最新情報をもっと見るRecent updatesお知らせ • Jul 06Atlas Energy Corp., Annual General Meeting, Aug 06, 2026Atlas Energy Corp., Annual General Meeting, Aug 06, 2026.お知らせ • Jun 22Atlas Energy Corp. Announces Appointments to Subsidiary BoardAtlas Energy Corp. announced that Patrick Drouin and Dion Degrand will be appointed to the board of directors of Atlas Energy International SEZC, the Company’s Cayman Islands subsidiary, subject to receipt of applicable Cayman Islands regulatory approvals. Patrick Drouin is the President of Wheaton Precious Metals International and Chief Sustainability Officer for the Wheaton group. Before being appointed President in October 2023, Mr. Drouin was the Senior Vice President of Sustainability & Investor Relations at Wheaton Precious Metals, an executive role primarily responsible for the company’s sustainability efforts and engaging with the investment community. Prior to Wheaton, Mr. Drouin worked for UBS Securities from 2001 to 2012 in institutional equity sales across North America and Europe, most recently in London as Head of European Sales for UBS Canada. In this role, Mr. Drouin built a sales platform responsible for advising fund managers on Canadian equities. Throughout his advisory career, he has focused on the resource sector. Prior to UBS, he served as a Project Geologist in the San Francisco Bay Area for William Lettis & Associates. Mr. Drouin has an MBA from the Rotman School of Management, University of Toronto, and a Masters in Geology from the University of Memphis. Dion Degrand is the Chief Executive Officer of the Rawlinson & Hunter group of companies in the Cayman Islands, providing a full range of professional services including fiduciary, trust and corporate, fund governance and administration, accounting, restructuring and compliance services to international clients. Mr. Degrand has over 30 years of experience across investment banking, public and private capital markets, accounting, international banking, and independent governance. Prior to relocating to the Cayman Islands, Mr. Degrand spent the majority of his career in oil and gas investment banking, holding senior positions at leading investment banks, including Head of Canadian Energy at Raymond James (Canada), Head of Energy and Head of Western Canada at Cormark Securities, Managing Director at National Bank Financial and Principal at Peters & Co. Limited. Mr. Degrand is a CA, CPA and CFA charterholder, and a CIMA-registered director under the Cayman Islands Directors Registration and Licensing Act.お知らせ • Jun 19+ 2 more updatesWillow Biosciences Inc. Announces Board and Executive AppointmentsWillow Biosciences Inc. announced the new management team and new board were appointed concurrently with the completion of the Private Placement, led by Mark Hodgson as President and Richard Naden as a Senior Executive and including Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price as directors. In addition, Sanjib (Sony) Gill, a partner in the Calgary office of the national law firm Stikeman Elliott LLP, will act as Corporate Secretary. The new management team expects to focus on investing in producing and growth-oriented oil and gas assets aligned with their prior operating expertise. With a disciplined and diversified strategy, the Company will aim to acquire economic interests in undercapitalized assets that have been overlooked amid recent shifts in capital allocation within the industry. The new management team is actively evaluating numerous opportunities.お知らせ • May 07Willow Biosciences Inc. announced that it expects to receive CAD 30 million in fundingWillow Biosciences Inc. announced a private placement of 3,000,000,000 common shares and units at a price of CAD 0.01 for the gross proceeds of CAD 30,000,000 on May 7, 2025. Each unit will consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of CAD 0.01 per share. The Company may pay fees to certain advisory firms that assist in the placement of the Private Placement. Units will be issued to subscribers that are members of the New Executive Team and the New Board, together with certain additional subscribers identified by such persons. Common Shares will be issued to all other subscribers. The New Executive Team will be led by Mark Hodgson as President and Chief Executive Officer, Travis Doupe as Chief Financial Officer, Don Kornelsen as Vice President, Commercial, Ryan Giroux as Vice President, Corporate Development and Blair Anderson as Vice President, Geoscience of the Company and Richard Naden as a Senior Executive. The New Board will be comprised of Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price.お知らせ • May 02+ 1 more updateWillow Biosciences Inc. Announces CEO ChangesWillow Biosciences Inc. announced the completion of the sale (the Transaction) of its wholly-owned operating subsidiary, Epimeron USA Inc. As a condition to the completion of the Transaction, Dr. Chris Savile, Chief Executive Officer of the Company resigned from the role with the Company to join the Purchaser. Travis Doupe, Chief Financial Officer of the Company, has been appointed to the role of Interim Chief Executive Officer effective April 30, 2025.お知らせ • May 01Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million.Mycofeast Ltd entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million on March 14, 2025. The acquisition includes the Company's biotechnology business, intellectual property and R&D team. The consideration is subject to working capital and net debt closing adjustments. Closing of the Transaction is expected to occur on or about April 30, 2025, subject to customary closing conditions. The Transaction must be approved by shareholders holding at least 66.67% of shares voted in person or by proxy at an annual general and special meeting of shareholders, which will be held April 25, 2025 (the "Meeting"). The Transaction has been approved unanimously by Willow's Board of Directors, which has determined that the Transaction is in the best interests of Willow and its shareholders and unanimously recommends that shareholders vote in favour of approving the Transaction at the Meeting. Willow's major shareholders, Directors and Officers, who collectively control approximately 22.17% of the outstanding common shares of Willow, have each entered into a voting support agreement pursuant to which they have irrevocably agreed to vote all common shares in favour of the Transaction at the Meeting. The Company intends to apply a portion of the net proceeds to debt reduction, and will retain the remainder of the proceeds pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value. Willow Biosciences Inc. must pay $0.5 million to Mycofeast Ltd if it terminates the deal. The deal is expected to be closed before April 30, 2025. Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million on April 30, 2025.お知らせ • Mar 27Willow Biosciences Inc. Auditor Raises 'Going Concern' DoubtWillow Biosciences Inc. filed its Annual on Mar 25, 2025 for the period ending Dec 31, 2024. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Mar 19Willow Biosciences Inc., Annual General Meeting, Apr 25, 2025Willow Biosciences Inc., Annual General Meeting, Apr 25, 2025.お知らせ • Mar 16An undisclosed buyer entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million.An undisclosed buyer entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million on March 14, 2025. The acquisition includes the Company's biotechnology business, intellectual property and R&D team. The consideration is subject to working capital and net debt closing adjustments. Closing of the Transaction is expected to occur on or about April 30, 2025, subject to customary closing conditions. The Transaction must be approved by shareholders holding at least 66.67% of shares voted in person or by proxy at an annual general and special meeting of shareholders, which will be held April 25, 2025 (the "Meeting"). The Transaction has been approved unanimously by Willow's Board of Directors, which has determined that the Transaction is in the best interests of Willow and its shareholders and unanimously recommends that shareholders vote in favour of approving the Transaction at the Meeting. Willow's major shareholders, Directors and Officers, who collectively control approximately 22.17% of the outstanding common shares of Willow, have each entered into a voting support agreement pursuant to which they have irrevocably agreed to vote all common shares in favour of the Transaction at the Meeting. The Company intends to apply a portion of the net proceeds to debt reduction, and will retain the remainder of the proceeds pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value.お知らせ • Nov 18Willow Biosciences Inc. announced that it expects to receive CAD 2.001341 million in fundingWillow Biosciences Inc. announced a non-brokered private placement on a best efforts basis of a minimum of 10,000,000 units at a price of CAD 0.08 per unit for minimum gross proceeds of CAD 800,000; and a maximum of up to 25,016,762 units at a price of CAD 0.08 per unit for maximum gross proceeds of CAD 2,001,340.96 on November 18, 2024.Each unit shall consist of one common share and one-half of one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at an exercise price of CAD 0.11 per common share for a period of 36 months from the closing of the offering. The closing will take place on such date or dates as may be determined by the company, and, in any event, on or before January 2, 2025. The closing of the offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX. The company may pay a finder's fee in connection with the offering to eligible arm's length finders in accordance with the policies of the TSX.お知らせ • Aug 13Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024Willow Biosciences Inc. provided earnings guidance for the fiscal year 2024. The Company remains steadfast in its revenue expectations for Fiscal Year 2024 revenues To be in excess of $4 million, an increase of almost 350% over 2023. This revenue expectation for Fiscal year 2024 is forecast to be driven from existing programs. In addition to the new programs that have already been announced so far in 2024, the Company expects to add at least one more fully funded, partnered program as well as one new internal program before the end of 2024.お知らせ • Jul 18Willow Biosciences Inc. announced that it has received CAD 1.639737 million in fundingOn July 18, 2024, Willow Biosciences Inc closed the transaction. The company issued 16,397,365 units at an issue price of CAD 0.10 per Unit to raise aggregate gross proceeds of up to CAD 1,639,736.50. The Agent received a cash commission of $86,992.10 and was issued 869,921 non-transferable broker warrants. Each Broker Warrant will entitle the Agent to purchase one (1) Unit for a period of 36 months following Closing, with 824,921 Broker Warrants being exercisable at the Issue Price, and 45,000 Broker Warrants being exercisable at the Exercise Price. The Offering remains subject to the final approval of the TSX.お知らせ • Jun 08Willow Biosciences Inc., Annual General Meeting, Jul 26, 2024Willow Biosciences Inc., Annual General Meeting, Jul 26, 2024.お知らせ • Jun 05Willow Biosciences Inc. announced that it expects to receive CAD 3 million in fundingWillow Biosciences Inc. announced a private placement of 30,000,000 units at an issue price of CAD 0.10 per Unit to raise aggregate gross proceeds of up to CAD 3,000,000 on June 3, 2024. Each Unit issued under the Offering shall consist of one common share in the capital of the Company and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of CAD 0.13 per Common Share for a period of 36 months from the closing of the Offering. The Closing will take place on such date or dates as may be agreed upon by the Company and the Agent, and, in any event, on or before July 18, 2024, being the date that is 45 days from the date hereof. Closing of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX. The Company has also granted the Agent an option, exercisable in whole or in part, to sell such number of additional Units, as is equal to 15% of the number of Units of the Company issued pursuant to the Offering. The Over-Allotment Option may be exercised by the Agent for a period of 30 days from and including the Closing.お知らせ • Feb 21Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.Willow Biosciences Inc. announced a non-brokered equity private placement to issue units at a issue price of CAD 0.10 per Unit to new investor, Kalsec Inc on February 20, 2024. Each Unit consisting of one common share and one-half of one Common Share purchase warrant. Each Warrant entitles the holder thereof to purchase one Common Share at a price of CAD 0.14 per Common Share until February 20, 2025; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Common Shares on the Toronto Stock Exchange or other principal exchange on which the Common Shares are listed, is greater than CAD 0.18, the company may accelerate the expiry date of the warrants to the date that is 20 days following the date of the notice of such acceleration. Subject to the completion of an operational milestone by Willow to develop a strain that meets certain performance criteria, Kalsec agreed to subscribe for and purchase an additional CAD 135,141($100,000) of Units at a price per Unit equal to the greater of CAD 0.10; and a discount of 10% to the volume weighted average trading price of Common Shares on the TSX for the five business days ended on the completion date of the Milestone. All securities issued under the Financing, including securities issuable on exercise thereof, are subject to a hold period in Canada of four months and one day in accordance with applicable securities legislation. On same date, the company issued 1,359,856 units at a subscription price of CAD 0.10 per Unit for gross proceeds CAD 135,985.6 in its first tranche.お知らせ • Oct 26Aurora Cannabis Inc. Announces Settlement of Patent Litigation with Willow Biosciences IncAurora Cannabis Inc. announced the company and WILLOW BIOSCIENCES, INC. (Willow) have successfully completed a confidential settlement resolving the ongoing patent litigation between the two parties in Canada. Aurora commenced a patent infringement action in July 2021, alleging that Willow's biosynthetic process for synthesizing cannabinoids infringed Aurora's exclusive rights to patents co-owned by the University of Saskatchewan and the National Research Council (NRC). The technology of the asserted patents was invented by Anandia co-founder and former Chief Science Officer at Aurora, Jonathan Page and his colleagues, following their work at the University of Saskatchewan and the NRC, identifying key enzymes and corresponding genes in the biosynthetic pathways of cannabis plants. In December 2022, Willow announced that it had consolidated its R&D operations, transferring equipment and key personnel from its Canadian facilities to Mountain View, California.お知らせ • Oct 12Willow Biosciences Inc. announced that it has received CAD 0.8 million in fundingOn October 10, 2023, Willow Biosciences Inc. closed the transaction. The company has received CAD 800,000 of the convertible debenture units. The Offering was led by insiders including members of the Board of Directors and members of the senior management team of the Company, who subscribed for a total of CAD 515,000. Each Debenture Unit consists of one 12% unsecured convertible debenture in the principal amount of CAD 1,000 due October 10, 2026 and 4,762 common share purchase warrants. Each Warrant entitles the holder thereof to purchase one common share of the Company at a price of CAD 0.105 per Share until October 10, 2025; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Shares on the Toronto Stock Exchange or other principal exchange on which the Shares are listed, is greater than CAD 0.15, the Company may accelerate the expiry date of the Warrants to the date that is 20 days following the date of the notice of such acceleration.お知らせ • Sep 14Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in fundingWillow Biosciences Inc. announce the offering of convertible debenture units for aggregate proceeds of up to CAD 1,200,000 on September 12, 2023.This offering is being led by insiders including members of the Board of Directors and members of the senior management team of the Company, who are expected to subscribe to approximately 50% of the total funds raised. The Offering is currently open only to accredited investors. Each Debenture Unit will consist of one 12% unsecured convertible debenture in the principal amount of CAD 1000 with a maturity date of 36 months after the closing of the financing and 4,762 common share purchase warrants. Each Warrant will entitle the holder thereof to purchase one common share of the Company at a price of CAD 0.105 per Share for a period of 24 months; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Shares on the Toronto Stock Exchange (the "TSX"), or other principal exchange on which the Shares are listed, is greater than CAD 0.15, the Company may accelerate the expiry date of the Warrants to the date that is 20 days following the date of the notice of such acceleration. The Convertible Debentures will be convertible at the holder's option into Shares at any time prior to the earlier of the business day immediately preceding the Maturity Date and the date fixed for redemption of the Convertible Debentures at a conversion price of CAD 0.105 per Share. Interest on the Convertible Debentures will be payable semi-annually in arrears, beginning on December 31, 2023.The offering is expected to close on or about September 29, 2023.All securities issued under the Offering, including securities issuable on conversion or exercise thereof, will be subject to a hold period in Canada of four months and one day following the Closing Date in accordance with applicable securities legislation.お知らせ • Sep 07Willow Biosciences Inc. Announces Successful Completion of R&D Program on CovidWillow Biosciences Inc. announced that it has successfully completed research and development on its program to produceursodeoxycholic acid ("UDCA"), a large volume active pharmaceutical ingredient ("API") used in nutraceutical and pharmaceutical products. UDCA has applications as a medication for management and treatment of cholestatic liver disease and gallstone conditions, and as an intermediate for production of tauroursodeoxycholic acid (TUDCA), a key API in a combination therapy recently approved in Canada and the United States for treatment of amyotrophic lateral sclerosis (ALS). Through this partnered program with Sandhill One, LLC ("Sandhill"), Willow has now optimized a proprietary enzyme vital to the development of UDCA while solving for selective C-H hydroxylation at industrial scale - often referred to as one of the "Holy Grails" of chemistry. This breakthrough was made possible by Willow's BioOxi technology, and believe marks the first example of commercially relevant productivities with this class of enzyme. This successful outcome further illustrates that the BioOxi platform is broadly applicable to the manufacturing of intermediates and APIs, particularly steroid APIs. With R&D now complete, Willow anticipates receiving milestone payments and revenue upon commercialization by Sandhill.お知らせ • Aug 31Willow Biosciences Inc. Announces Filing of Patent Application for Process to Produce Corticosteroids At Significantly Reduced CostWillow Biosciences Inc. announced the development of a process to produce corticosteroids at significantly reduced cost by utilizing its BioOxi platform for efficient bio-hydroxylation that can transform manufacturing. Corticosteroids are broadly used as anti-inflammatory and immunosuppressant drugs. According to independent research firm, ResearchandMarkets, the global corticosteroids market is expected to grow at a CAGR of 4.1% and reach $5.93 billion in 2026 and North America was the larger region for use of corticosteroids in 2022. A large percentage of corticosteroid production is outside the United States, which can pose supply chain security issues for drug manufacturers and potentially lead to drug shortages. Willow's innovative BioOxi process represents a step change by significantly reducing production costs and is expected to be sufficiently competitive to enable greater onshoring of corticosteroid manufacturing, leading to a more secure domestic supply chain. Coupled with pending patent protection, should it be granted, Willow believes this wholly-owned technology will provide a significant competitive advantage to potential pharmaceutical manufacturing partners. By leveraging BioOxi, commercial partners can revolutionize the manufacturing process of hydroxylated functional ingredients such as steroids, polyphenols, oxyterpenes, and other ingredients.お知らせ • Aug 25Willow Biosciences Inc. Announces Board ChangesWillow Biosciences Inc. announced that the company is reducing the size of its board of directors (the "Board") from nine to five members. Chairman of the Board and Founder of the Company, Mr. Trevor Peters, and Directors Ms. Barbara Munroe, Dr. Fotis Kalantzis and Dr. Peter Seufer-Wasserthal stepped down from the Board effective from August 24, 2023. The Board now consists of Dr. Chris Savile, Willow's President & CEO, Mr. Al Foreman, Mr. Raffi Asadorian, Mr. Don Archibald and Dr. Jim Lalonde. Dr. Jim Lalonde succeeds Mr. Peters as Chairman of the Board.お知らせ • May 13Willow Biosciences Inc. Announces Executive ChangesWillow Biosciences Inc. at the annual general and special meeting of shareholders held on May 12, 2023, Mr. Raffi Asadorian was appointed as an independent director to the board of directors of Willow to succeed Mr. Sadiq Lalani who had served on the Board since April 2019 and had decided not to stand for re-election due to other commitments.お知らせ • Jul 23Willow Biosciences to Commence Trading on The OTCQX® Best MarketWillow Biosciences Inc. announced that it has been approved to commence trading on the OTCQX® Best Market (the "OTCQX"), beginning, July 22, 2020, under the symbol "CANSF".株主還元CANS.FUS BiotechsUS 市場7D-3.4%-1.3%-1.1%1Y-40.9%28.8%15.1%株主還元を見る業界別リターン: CANS.F過去 1 年間で28.8 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: CANS.Fは、過去 1 年間で15.1 % のリターンを上げたUS市場を下回りました。価格変動Is CANS.F's price volatile compared to industry and market?CANS.F volatilityCANS.F Average Weekly Movementn/aBiotechs Industry Average Movement10.1%Market Average Movement7.1%10% most volatile stocks in US Market16.1%10% least volatile stocks in US Market3.2%安定した株価: CANS.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のCANS.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a9Mark Hodgsonwww.atlas-corp.caバイオテクノロジー企業であるウィロー・バイオサイエンシズ社は、米国でコンシューマーケア、食品・飲料、医薬品向けの植物由来原料を開発、生産、販売している。同社はLaurus Labs社とライセンス及び開発パートナーシップを結び、医薬品有効成分等の開発・商品化を行っている。ウィロー・バイオサイエンシズ・インクは2019年に設立され、カナダのカルガリーに本社を置いている。もっと見るAtlas Energy Corp. 基礎のまとめAtlas Energy の収益と売上を時価総額と比較するとどうか。CANS.F 基礎統計学時価総額US$58.03m収益（TTM）-US$2.49m売上高(TTM)n/a0.0xP/Sレシオ-23.3xPER（株価収益率CANS.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CANS.F 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$3.52m収益-CA$3.52m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.0056グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%CANS.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/25 21:46終値2026/07/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Atlas Energy Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関David KideckelATB Cormark
お知らせ • Jul 06Atlas Energy Corp., Annual General Meeting, Aug 06, 2026Atlas Energy Corp., Annual General Meeting, Aug 06, 2026.
お知らせ • Jun 22Atlas Energy Corp. Announces Appointments to Subsidiary BoardAtlas Energy Corp. announced that Patrick Drouin and Dion Degrand will be appointed to the board of directors of Atlas Energy International SEZC, the Company’s Cayman Islands subsidiary, subject to receipt of applicable Cayman Islands regulatory approvals. Patrick Drouin is the President of Wheaton Precious Metals International and Chief Sustainability Officer for the Wheaton group. Before being appointed President in October 2023, Mr. Drouin was the Senior Vice President of Sustainability & Investor Relations at Wheaton Precious Metals, an executive role primarily responsible for the company’s sustainability efforts and engaging with the investment community. Prior to Wheaton, Mr. Drouin worked for UBS Securities from 2001 to 2012 in institutional equity sales across North America and Europe, most recently in London as Head of European Sales for UBS Canada. In this role, Mr. Drouin built a sales platform responsible for advising fund managers on Canadian equities. Throughout his advisory career, he has focused on the resource sector. Prior to UBS, he served as a Project Geologist in the San Francisco Bay Area for William Lettis & Associates. Mr. Drouin has an MBA from the Rotman School of Management, University of Toronto, and a Masters in Geology from the University of Memphis. Dion Degrand is the Chief Executive Officer of the Rawlinson & Hunter group of companies in the Cayman Islands, providing a full range of professional services including fiduciary, trust and corporate, fund governance and administration, accounting, restructuring and compliance services to international clients. Mr. Degrand has over 30 years of experience across investment banking, public and private capital markets, accounting, international banking, and independent governance. Prior to relocating to the Cayman Islands, Mr. Degrand spent the majority of his career in oil and gas investment banking, holding senior positions at leading investment banks, including Head of Canadian Energy at Raymond James (Canada), Head of Energy and Head of Western Canada at Cormark Securities, Managing Director at National Bank Financial and Principal at Peters & Co. Limited. Mr. Degrand is a CA, CPA and CFA charterholder, and a CIMA-registered director under the Cayman Islands Directors Registration and Licensing Act.
お知らせ • Jun 19+ 2 more updatesWillow Biosciences Inc. Announces Board and Executive AppointmentsWillow Biosciences Inc. announced the new management team and new board were appointed concurrently with the completion of the Private Placement, led by Mark Hodgson as President and Richard Naden as a Senior Executive and including Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price as directors. In addition, Sanjib (Sony) Gill, a partner in the Calgary office of the national law firm Stikeman Elliott LLP, will act as Corporate Secretary. The new management team expects to focus on investing in producing and growth-oriented oil and gas assets aligned with their prior operating expertise. With a disciplined and diversified strategy, the Company will aim to acquire economic interests in undercapitalized assets that have been overlooked amid recent shifts in capital allocation within the industry. The new management team is actively evaluating numerous opportunities.
お知らせ • May 07Willow Biosciences Inc. announced that it expects to receive CAD 30 million in fundingWillow Biosciences Inc. announced a private placement of 3,000,000,000 common shares and units at a price of CAD 0.01 for the gross proceeds of CAD 30,000,000 on May 7, 2025. Each unit will consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of CAD 0.01 per share. The Company may pay fees to certain advisory firms that assist in the placement of the Private Placement. Units will be issued to subscribers that are members of the New Executive Team and the New Board, together with certain additional subscribers identified by such persons. Common Shares will be issued to all other subscribers. The New Executive Team will be led by Mark Hodgson as President and Chief Executive Officer, Travis Doupe as Chief Financial Officer, Don Kornelsen as Vice President, Commercial, Ryan Giroux as Vice President, Corporate Development and Blair Anderson as Vice President, Geoscience of the Company and Richard Naden as a Senior Executive. The New Board will be comprised of Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price.
お知らせ • May 02+ 1 more updateWillow Biosciences Inc. Announces CEO ChangesWillow Biosciences Inc. announced the completion of the sale (the Transaction) of its wholly-owned operating subsidiary, Epimeron USA Inc. As a condition to the completion of the Transaction, Dr. Chris Savile, Chief Executive Officer of the Company resigned from the role with the Company to join the Purchaser. Travis Doupe, Chief Financial Officer of the Company, has been appointed to the role of Interim Chief Executive Officer effective April 30, 2025.
お知らせ • May 01Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million.Mycofeast Ltd entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million on March 14, 2025. The acquisition includes the Company's biotechnology business, intellectual property and R&D team. The consideration is subject to working capital and net debt closing adjustments. Closing of the Transaction is expected to occur on or about April 30, 2025, subject to customary closing conditions. The Transaction must be approved by shareholders holding at least 66.67% of shares voted in person or by proxy at an annual general and special meeting of shareholders, which will be held April 25, 2025 (the "Meeting"). The Transaction has been approved unanimously by Willow's Board of Directors, which has determined that the Transaction is in the best interests of Willow and its shareholders and unanimously recommends that shareholders vote in favour of approving the Transaction at the Meeting. Willow's major shareholders, Directors and Officers, who collectively control approximately 22.17% of the outstanding common shares of Willow, have each entered into a voting support agreement pursuant to which they have irrevocably agreed to vote all common shares in favour of the Transaction at the Meeting. The Company intends to apply a portion of the net proceeds to debt reduction, and will retain the remainder of the proceeds pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value. Willow Biosciences Inc. must pay $0.5 million to Mycofeast Ltd if it terminates the deal. The deal is expected to be closed before April 30, 2025. Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million on April 30, 2025.
お知らせ • Jul 06Atlas Energy Corp., Annual General Meeting, Aug 06, 2026Atlas Energy Corp., Annual General Meeting, Aug 06, 2026.
お知らせ • Jun 22Atlas Energy Corp. Announces Appointments to Subsidiary BoardAtlas Energy Corp. announced that Patrick Drouin and Dion Degrand will be appointed to the board of directors of Atlas Energy International SEZC, the Company’s Cayman Islands subsidiary, subject to receipt of applicable Cayman Islands regulatory approvals. Patrick Drouin is the President of Wheaton Precious Metals International and Chief Sustainability Officer for the Wheaton group. Before being appointed President in October 2023, Mr. Drouin was the Senior Vice President of Sustainability & Investor Relations at Wheaton Precious Metals, an executive role primarily responsible for the company’s sustainability efforts and engaging with the investment community. Prior to Wheaton, Mr. Drouin worked for UBS Securities from 2001 to 2012 in institutional equity sales across North America and Europe, most recently in London as Head of European Sales for UBS Canada. In this role, Mr. Drouin built a sales platform responsible for advising fund managers on Canadian equities. Throughout his advisory career, he has focused on the resource sector. Prior to UBS, he served as a Project Geologist in the San Francisco Bay Area for William Lettis & Associates. Mr. Drouin has an MBA from the Rotman School of Management, University of Toronto, and a Masters in Geology from the University of Memphis. Dion Degrand is the Chief Executive Officer of the Rawlinson & Hunter group of companies in the Cayman Islands, providing a full range of professional services including fiduciary, trust and corporate, fund governance and administration, accounting, restructuring and compliance services to international clients. Mr. Degrand has over 30 years of experience across investment banking, public and private capital markets, accounting, international banking, and independent governance. Prior to relocating to the Cayman Islands, Mr. Degrand spent the majority of his career in oil and gas investment banking, holding senior positions at leading investment banks, including Head of Canadian Energy at Raymond James (Canada), Head of Energy and Head of Western Canada at Cormark Securities, Managing Director at National Bank Financial and Principal at Peters & Co. Limited. Mr. Degrand is a CA, CPA and CFA charterholder, and a CIMA-registered director under the Cayman Islands Directors Registration and Licensing Act.
お知らせ • Jun 19+ 2 more updatesWillow Biosciences Inc. Announces Board and Executive AppointmentsWillow Biosciences Inc. announced the new management team and new board were appointed concurrently with the completion of the Private Placement, led by Mark Hodgson as President and Richard Naden as a Senior Executive and including Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price as directors. In addition, Sanjib (Sony) Gill, a partner in the Calgary office of the national law firm Stikeman Elliott LLP, will act as Corporate Secretary. The new management team expects to focus on investing in producing and growth-oriented oil and gas assets aligned with their prior operating expertise. With a disciplined and diversified strategy, the Company will aim to acquire economic interests in undercapitalized assets that have been overlooked amid recent shifts in capital allocation within the industry. The new management team is actively evaluating numerous opportunities.
お知らせ • May 07Willow Biosciences Inc. announced that it expects to receive CAD 30 million in fundingWillow Biosciences Inc. announced a private placement of 3,000,000,000 common shares and units at a price of CAD 0.01 for the gross proceeds of CAD 30,000,000 on May 7, 2025. Each unit will consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of CAD 0.01 per share. The Company may pay fees to certain advisory firms that assist in the placement of the Private Placement. Units will be issued to subscribers that are members of the New Executive Team and the New Board, together with certain additional subscribers identified by such persons. Common Shares will be issued to all other subscribers. The New Executive Team will be led by Mark Hodgson as President and Chief Executive Officer, Travis Doupe as Chief Financial Officer, Don Kornelsen as Vice President, Commercial, Ryan Giroux as Vice President, Corporate Development and Blair Anderson as Vice President, Geoscience of the Company and Richard Naden as a Senior Executive. The New Board will be comprised of Mark Hodgson, Richard F. McHardy, Gary Brown, Glenn McNamara and Scott Price.
お知らせ • May 02+ 1 more updateWillow Biosciences Inc. Announces CEO ChangesWillow Biosciences Inc. announced the completion of the sale (the Transaction) of its wholly-owned operating subsidiary, Epimeron USA Inc. As a condition to the completion of the Transaction, Dr. Chris Savile, Chief Executive Officer of the Company resigned from the role with the Company to join the Purchaser. Travis Doupe, Chief Financial Officer of the Company, has been appointed to the role of Interim Chief Executive Officer effective April 30, 2025.
お知らせ • May 01Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million.Mycofeast Ltd entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million on March 14, 2025. The acquisition includes the Company's biotechnology business, intellectual property and R&D team. The consideration is subject to working capital and net debt closing adjustments. Closing of the Transaction is expected to occur on or about April 30, 2025, subject to customary closing conditions. The Transaction must be approved by shareholders holding at least 66.67% of shares voted in person or by proxy at an annual general and special meeting of shareholders, which will be held April 25, 2025 (the "Meeting"). The Transaction has been approved unanimously by Willow's Board of Directors, which has determined that the Transaction is in the best interests of Willow and its shareholders and unanimously recommends that shareholders vote in favour of approving the Transaction at the Meeting. Willow's major shareholders, Directors and Officers, who collectively control approximately 22.17% of the outstanding common shares of Willow, have each entered into a voting support agreement pursuant to which they have irrevocably agreed to vote all common shares in favour of the Transaction at the Meeting. The Company intends to apply a portion of the net proceeds to debt reduction, and will retain the remainder of the proceeds pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value. Willow Biosciences Inc. must pay $0.5 million to Mycofeast Ltd if it terminates the deal. The deal is expected to be closed before April 30, 2025. Mycofeast Ltd completed the acquisition of Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $2.76 million on April 30, 2025.
お知らせ • Mar 27Willow Biosciences Inc. Auditor Raises 'Going Concern' DoubtWillow Biosciences Inc. filed its Annual on Mar 25, 2025 for the period ending Dec 31, 2024. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Mar 19Willow Biosciences Inc., Annual General Meeting, Apr 25, 2025Willow Biosciences Inc., Annual General Meeting, Apr 25, 2025.
お知らせ • Mar 16An undisclosed buyer entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million.An undisclosed buyer entered into a definitive agreement to acquire Epimeron USA, Inc. from Willow Biosciences Inc. (TSX:WLLW) for $3.4 million on March 14, 2025. The acquisition includes the Company's biotechnology business, intellectual property and R&D team. The consideration is subject to working capital and net debt closing adjustments. Closing of the Transaction is expected to occur on or about April 30, 2025, subject to customary closing conditions. The Transaction must be approved by shareholders holding at least 66.67% of shares voted in person or by proxy at an annual general and special meeting of shareholders, which will be held April 25, 2025 (the "Meeting"). The Transaction has been approved unanimously by Willow's Board of Directors, which has determined that the Transaction is in the best interests of Willow and its shareholders and unanimously recommends that shareholders vote in favour of approving the Transaction at the Meeting. Willow's major shareholders, Directors and Officers, who collectively control approximately 22.17% of the outstanding common shares of Willow, have each entered into a voting support agreement pursuant to which they have irrevocably agreed to vote all common shares in favour of the Transaction at the Meeting. The Company intends to apply a portion of the net proceeds to debt reduction, and will retain the remainder of the proceeds pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value.
お知らせ • Nov 18Willow Biosciences Inc. announced that it expects to receive CAD 2.001341 million in fundingWillow Biosciences Inc. announced a non-brokered private placement on a best efforts basis of a minimum of 10,000,000 units at a price of CAD 0.08 per unit for minimum gross proceeds of CAD 800,000; and a maximum of up to 25,016,762 units at a price of CAD 0.08 per unit for maximum gross proceeds of CAD 2,001,340.96 on November 18, 2024.Each unit shall consist of one common share and one-half of one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at an exercise price of CAD 0.11 per common share for a period of 36 months from the closing of the offering. The closing will take place on such date or dates as may be determined by the company, and, in any event, on or before January 2, 2025. The closing of the offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX. The company may pay a finder's fee in connection with the offering to eligible arm's length finders in accordance with the policies of the TSX.
お知らせ • Aug 13Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024Willow Biosciences Inc. provided earnings guidance for the fiscal year 2024. The Company remains steadfast in its revenue expectations for Fiscal Year 2024 revenues To be in excess of $4 million, an increase of almost 350% over 2023. This revenue expectation for Fiscal year 2024 is forecast to be driven from existing programs. In addition to the new programs that have already been announced so far in 2024, the Company expects to add at least one more fully funded, partnered program as well as one new internal program before the end of 2024.
お知らせ • Jul 18Willow Biosciences Inc. announced that it has received CAD 1.639737 million in fundingOn July 18, 2024, Willow Biosciences Inc closed the transaction. The company issued 16,397,365 units at an issue price of CAD 0.10 per Unit to raise aggregate gross proceeds of up to CAD 1,639,736.50. The Agent received a cash commission of $86,992.10 and was issued 869,921 non-transferable broker warrants. Each Broker Warrant will entitle the Agent to purchase one (1) Unit for a period of 36 months following Closing, with 824,921 Broker Warrants being exercisable at the Issue Price, and 45,000 Broker Warrants being exercisable at the Exercise Price. The Offering remains subject to the final approval of the TSX.
お知らせ • Jun 08Willow Biosciences Inc., Annual General Meeting, Jul 26, 2024Willow Biosciences Inc., Annual General Meeting, Jul 26, 2024.
お知らせ • Jun 05Willow Biosciences Inc. announced that it expects to receive CAD 3 million in fundingWillow Biosciences Inc. announced a private placement of 30,000,000 units at an issue price of CAD 0.10 per Unit to raise aggregate gross proceeds of up to CAD 3,000,000 on June 3, 2024. Each Unit issued under the Offering shall consist of one common share in the capital of the Company and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of CAD 0.13 per Common Share for a period of 36 months from the closing of the Offering. The Closing will take place on such date or dates as may be agreed upon by the Company and the Agent, and, in any event, on or before July 18, 2024, being the date that is 45 days from the date hereof. Closing of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX. The Company has also granted the Agent an option, exercisable in whole or in part, to sell such number of additional Units, as is equal to 15% of the number of Units of the Company issued pursuant to the Offering. The Over-Allotment Option may be exercised by the Agent for a period of 30 days from and including the Closing.
お知らせ • Feb 21Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.Willow Biosciences Inc. announced a non-brokered equity private placement to issue units at a issue price of CAD 0.10 per Unit to new investor, Kalsec Inc on February 20, 2024. Each Unit consisting of one common share and one-half of one Common Share purchase warrant. Each Warrant entitles the holder thereof to purchase one Common Share at a price of CAD 0.14 per Common Share until February 20, 2025; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Common Shares on the Toronto Stock Exchange or other principal exchange on which the Common Shares are listed, is greater than CAD 0.18, the company may accelerate the expiry date of the warrants to the date that is 20 days following the date of the notice of such acceleration. Subject to the completion of an operational milestone by Willow to develop a strain that meets certain performance criteria, Kalsec agreed to subscribe for and purchase an additional CAD 135,141($100,000) of Units at a price per Unit equal to the greater of CAD 0.10; and a discount of 10% to the volume weighted average trading price of Common Shares on the TSX for the five business days ended on the completion date of the Milestone. All securities issued under the Financing, including securities issuable on exercise thereof, are subject to a hold period in Canada of four months and one day in accordance with applicable securities legislation. On same date, the company issued 1,359,856 units at a subscription price of CAD 0.10 per Unit for gross proceeds CAD 135,985.6 in its first tranche.
お知らせ • Oct 26Aurora Cannabis Inc. Announces Settlement of Patent Litigation with Willow Biosciences IncAurora Cannabis Inc. announced the company and WILLOW BIOSCIENCES, INC. (Willow) have successfully completed a confidential settlement resolving the ongoing patent litigation between the two parties in Canada. Aurora commenced a patent infringement action in July 2021, alleging that Willow's biosynthetic process for synthesizing cannabinoids infringed Aurora's exclusive rights to patents co-owned by the University of Saskatchewan and the National Research Council (NRC). The technology of the asserted patents was invented by Anandia co-founder and former Chief Science Officer at Aurora, Jonathan Page and his colleagues, following their work at the University of Saskatchewan and the NRC, identifying key enzymes and corresponding genes in the biosynthetic pathways of cannabis plants. In December 2022, Willow announced that it had consolidated its R&D operations, transferring equipment and key personnel from its Canadian facilities to Mountain View, California.
お知らせ • Oct 12Willow Biosciences Inc. announced that it has received CAD 0.8 million in fundingOn October 10, 2023, Willow Biosciences Inc. closed the transaction. The company has received CAD 800,000 of the convertible debenture units. The Offering was led by insiders including members of the Board of Directors and members of the senior management team of the Company, who subscribed for a total of CAD 515,000. Each Debenture Unit consists of one 12% unsecured convertible debenture in the principal amount of CAD 1,000 due October 10, 2026 and 4,762 common share purchase warrants. Each Warrant entitles the holder thereof to purchase one common share of the Company at a price of CAD 0.105 per Share until October 10, 2025; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Shares on the Toronto Stock Exchange or other principal exchange on which the Shares are listed, is greater than CAD 0.15, the Company may accelerate the expiry date of the Warrants to the date that is 20 days following the date of the notice of such acceleration.
お知らせ • Sep 14Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in fundingWillow Biosciences Inc. announce the offering of convertible debenture units for aggregate proceeds of up to CAD 1,200,000 on September 12, 2023.This offering is being led by insiders including members of the Board of Directors and members of the senior management team of the Company, who are expected to subscribe to approximately 50% of the total funds raised. The Offering is currently open only to accredited investors. Each Debenture Unit will consist of one 12% unsecured convertible debenture in the principal amount of CAD 1000 with a maturity date of 36 months after the closing of the financing and 4,762 common share purchase warrants. Each Warrant will entitle the holder thereof to purchase one common share of the Company at a price of CAD 0.105 per Share for a period of 24 months; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Shares on the Toronto Stock Exchange (the "TSX"), or other principal exchange on which the Shares are listed, is greater than CAD 0.15, the Company may accelerate the expiry date of the Warrants to the date that is 20 days following the date of the notice of such acceleration. The Convertible Debentures will be convertible at the holder's option into Shares at any time prior to the earlier of the business day immediately preceding the Maturity Date and the date fixed for redemption of the Convertible Debentures at a conversion price of CAD 0.105 per Share. Interest on the Convertible Debentures will be payable semi-annually in arrears, beginning on December 31, 2023.The offering is expected to close on or about September 29, 2023.All securities issued under the Offering, including securities issuable on conversion or exercise thereof, will be subject to a hold period in Canada of four months and one day following the Closing Date in accordance with applicable securities legislation.
お知らせ • Sep 07Willow Biosciences Inc. Announces Successful Completion of R&D Program on CovidWillow Biosciences Inc. announced that it has successfully completed research and development on its program to produceursodeoxycholic acid ("UDCA"), a large volume active pharmaceutical ingredient ("API") used in nutraceutical and pharmaceutical products. UDCA has applications as a medication for management and treatment of cholestatic liver disease and gallstone conditions, and as an intermediate for production of tauroursodeoxycholic acid (TUDCA), a key API in a combination therapy recently approved in Canada and the United States for treatment of amyotrophic lateral sclerosis (ALS). Through this partnered program with Sandhill One, LLC ("Sandhill"), Willow has now optimized a proprietary enzyme vital to the development of UDCA while solving for selective C-H hydroxylation at industrial scale - often referred to as one of the "Holy Grails" of chemistry. This breakthrough was made possible by Willow's BioOxi technology, and believe marks the first example of commercially relevant productivities with this class of enzyme. This successful outcome further illustrates that the BioOxi platform is broadly applicable to the manufacturing of intermediates and APIs, particularly steroid APIs. With R&D now complete, Willow anticipates receiving milestone payments and revenue upon commercialization by Sandhill.
お知らせ • Aug 31Willow Biosciences Inc. Announces Filing of Patent Application for Process to Produce Corticosteroids At Significantly Reduced CostWillow Biosciences Inc. announced the development of a process to produce corticosteroids at significantly reduced cost by utilizing its BioOxi platform for efficient bio-hydroxylation that can transform manufacturing. Corticosteroids are broadly used as anti-inflammatory and immunosuppressant drugs. According to independent research firm, ResearchandMarkets, the global corticosteroids market is expected to grow at a CAGR of 4.1% and reach $5.93 billion in 2026 and North America was the larger region for use of corticosteroids in 2022. A large percentage of corticosteroid production is outside the United States, which can pose supply chain security issues for drug manufacturers and potentially lead to drug shortages. Willow's innovative BioOxi process represents a step change by significantly reducing production costs and is expected to be sufficiently competitive to enable greater onshoring of corticosteroid manufacturing, leading to a more secure domestic supply chain. Coupled with pending patent protection, should it be granted, Willow believes this wholly-owned technology will provide a significant competitive advantage to potential pharmaceutical manufacturing partners. By leveraging BioOxi, commercial partners can revolutionize the manufacturing process of hydroxylated functional ingredients such as steroids, polyphenols, oxyterpenes, and other ingredients.
お知らせ • Aug 25Willow Biosciences Inc. Announces Board ChangesWillow Biosciences Inc. announced that the company is reducing the size of its board of directors (the "Board") from nine to five members. Chairman of the Board and Founder of the Company, Mr. Trevor Peters, and Directors Ms. Barbara Munroe, Dr. Fotis Kalantzis and Dr. Peter Seufer-Wasserthal stepped down from the Board effective from August 24, 2023. The Board now consists of Dr. Chris Savile, Willow's President & CEO, Mr. Al Foreman, Mr. Raffi Asadorian, Mr. Don Archibald and Dr. Jim Lalonde. Dr. Jim Lalonde succeeds Mr. Peters as Chairman of the Board.
お知らせ • May 13Willow Biosciences Inc. Announces Executive ChangesWillow Biosciences Inc. at the annual general and special meeting of shareholders held on May 12, 2023, Mr. Raffi Asadorian was appointed as an independent director to the board of directors of Willow to succeed Mr. Sadiq Lalani who had served on the Board since April 2019 and had decided not to stand for re-election due to other commitments.
お知らせ • Jul 23Willow Biosciences to Commence Trading on The OTCQX® Best MarketWillow Biosciences Inc. announced that it has been approved to commence trading on the OTCQX® Best Market (the "OTCQX"), beginning, July 22, 2020, under the symbol "CANSF".
